For many years, the primary forms of cancer treatment have been chemotherapy, radiation and surgery. An amazing breakthrough known as Chimeric Antigen Receptor T cell therapy (CAR T cell therapy) is now being studied in the treatment of various types of cancer, including acute myeloid leukemia, myelodysplastic syndromes, acute lymphoblastic leukemia, blastic plasmacytoid dendritic cell neoplasm and lymphoma.
CAR T cell therapy, or adoptive cell therapy, is a type of treatment in which a patient’s own T cells are manipulated in a lab by adding an artificial receptor, or a “CAR.” In conjunction with the patient’s own T cells, the CAR enables the final product to produce chemicals in the hopes that the “enhanced” product or cells will bind to the cancer cells and kill them.
Some of these unique therapies have already been approved by the US Food and Drug Administration (FDA) and are the first steps toward further groundbreaking science.
Join this live webinar as our featured speakers review the operational and clinical pathways that are helping to bring these technologies to patients.
Brian D. Marks, BSc, DC, Senior Director, Project Delivery, Oncology, Premier Research
Dr. Brian Marks has worked in clinical research for more than 20 years, covering the entire spectrum of trials from single-site studies to large, multinational trials. He joined Premier Research in 2018 to oversee and manage the oncology franchise (business unit), ensuring the program progressed according to client and Premier Research requirements. He also recommends and drives necessary courses of action to keep the program on track. Dr. Marks oversees OMCs and joint steering committees, monitors the health and growth of mission‐critical accounts and assists in the creation, development and nurturing of key strategic customer relationships.
Prior to joining Premier Research, Dr. Marks was a director of strategic initiative management, director of project management and a senior project manager at ICON clinical research. At GlaxoSmithKline, he was a manager of study management, program lead and a lead study manager.
Brian Marks received his Doctorate in Chiropractic as well as his Bachelor’s of Science in Human Biology from Logan College of Chiropractic.Message Presenter
Ashley Jones, MSc, Project Leader, Project Management, Oncology, Premier Research
Ashley joined the Premier Research team as a senior project manager in 2017. Prior to joining Premier Research, she worked for Quintiles for seven years, with four years in project management and three years in clinical management. Ashley was integral in the creation of the Stem Cell Center of Excellence at Quintiles, and currently helps develop strategies for CAR T and other immuno-oncology opportunities at Premier.
Ashley’s therapeutic expertise includes phase I-III oncology studies conducted in the US and globally with a special interest in pediatric hematopoietic stem cell transplantation and graft versus host disease, as well as phase Iand II acute lymphoblastic leukemia studies and phase I and II studies in advanced malignancies.Message Presenter
Who Should Attend?
This webinar will appeal to VPs, Directors, Managers, Department Heads, Scientists and Researchers working within:
- Clinical Affairs
- Clinical R&D
- Clinical Research
- Clinical Pharmacology
- Clinical Operations
- Project Management
- Regulatory Affairs
- Medical Affairs
What You Will Learn
In this webinar, attendees will explore:
- Principles of CAR T cell therapy
- FDA-approved CAR T cell therapies
- Operational and clinical pathways that bring CAR T cell therapies to patients
- Challenges with clinical application
Premier Research, a mid-size clinical research company, is dedicated to helping biotech, specialty pharma, and device innovators transform life-changing ideas and breakthrough science into new medical treatments.
As a global company, Premier specializes in the use of innovative technologies for smart study design and trial management to deliver clean, conclusive data to sponsors.
Whether it’s developing product lifecycle strategies, reducing clinical development cycle times, securing access to patients, navigating global regulations, maximizing the impact of limited rare disease data, or providing expertise in specific therapeutic areas, Premier is committed to helping its customers answer the unmet needs of patients across a broad range of medical conditions.